ABAyşe Elif Boncukcuoğlu

Ayşe Elif Boncukcuoğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşe Elif Boncukcuoğlu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A rare and unusual neurological finding of Behcet’s disease: intracranial hypotension

    by Ayşe Elif Boncukcuoğlu, Ayşenur Yılmaz, Mehmet Karagülle, Cemal Bes

  • Open Access

    The effect of pulmonary nodule presence on disease severity and course in ANCA-associated vasculitis: a multicenter cohort study

    by Ayşe Elif Boncukcuoğlu, Muhammed Faruk Kazanbaş, Akın Işık, Sevgi Bilen Ayhan, Meysere Nur Akuç, Burcu Ceren Ekti Uludoğan, Mehmet Ali Enlice, İzZet Selçuk Parlak, Esra Gemici, Ebru Aşıcıoğlu, et al.

  • Real-world evidence on JAK inhibitors in rheumatology practice: comparative safety, efficacy, and outcomes between JAK inhibitors

    by Rabia Deniz, Ayşenur Yılmaz, Ayşe Elif Boncukcuoğlu, Erdem Bektaş, Rumeysa Mirza Altıntaş, Hazal Ceylan Tan, Kübra Uğur, Gül Güzelant Özköse, Kübra Kalkan, Cemal Bes

    Janus kinase inhibitors (JAKinibs) are increasingly used in rheumatic diseases, yet comparative real-world data on retention, safety, and prescribing patterns remain limited. We evaluated drug survival, adverse events, and discontinuation for three JAKinibs. This retrospective, three-arm comparative cohort included patients with rheumatic diseases who received ≥ 1 JAKinib between May 2020 and July 2025. We included 185 patients(median age 44 years, 67.0% female) with seropositive RA (n = 87), seronegative RA (n = 36), ankylosing spondylitis (n = 39), psoriatic arthritis(n = 17), and others(n = 6). Tofacitinib was prescribed in 94 patients(50.8%), baricitinib in 45 (24.3%), and upadacitinib in 69 (37.3%). Most (89.7%) received one JAKinib. Tofacitinib, baricitinib, and upadacitinib were initiated as first JAKinib in 95.7%, 86.7%, and 81.2% of cases, respectively(p = 0.012). At last follow-up, 58.9% remained on any JAKinib. Six-month survival was 81.9% for tofacitinib, 77.8% for baricitinib, and 69.6% for upadacitinib(p = 0.049); median survival was 16.5, 17, and 11 months, respectively (p < 0.001). Secondary non-response was the leading cause of discontinuation, with adverse events accounting for less than 10%. JAKinibs showed favourable retention and safety. Treatment sequencing and early access influenced persistence; tofacitinib predominated due to early availability and prior use in biologic-naive patients, while upadacitinib was mainly prescribed after advanced therapy failure yet remained effective in refractory cases. Key Points • JAKinibs remain effective and tolerable across a range of inflammatory rheumatic diseases,regardless of prior biologic exposure or treatment line. • Upadacitinib, although often prescribed after failure of multiple advanced therapies andother JAKinibs, showed high continuation and retention rates, highlighting its role as a viablelate-line option. • Secondary unresponsiveness is the primary barrier to long-term JAKinib persistence,suggesting a need for early recognition and individualized treatment.

  • Thrombotic microangiopathy in adult with SAMD9L-associated autoinflammatory disease: a case report of a novel SAMD9L variant

    by Ayşe Elif Boncukcuoğlu, Rabia Deniz, Fatma Dilara Yürük Kıtay, Aydeniz Aydın Gümüş, Cemal Bes

  • Open Access

    Clinical Features and Phenotypic Similarities of Patients with Familial Behçet’s Disease

    by Kerem Abacar, Ayşe Elif Boncukcuoğlu, Rabia Deniz, Burcu Ceren Uludogan, Dilara Kaş, Elifnur Alkan, Gamzenur Kaya, Tuğçe Bozkurt, Nazife Şule Yaşar Bilge, Cemal Bes, et al.

    Background: Behçet’s disease (BD) exhibits significant phenotypic diversity. The genetic basis of phenotypic variations in BD has not yet been elucidated. Based on the high frequency of familial BD, we aimed to analyze the familial aggregation of various manifestations of BD in this study. Methods: Patients with BD from 3 Turkish tertiary rheumatology outpatient clinics were evaluated. Demographic and clinical characteristics of the familial group with either a first- or second-degree relative with BD and the non-familial group were compared. Afterward, patients in the familial disease group for 5 years or longer were divided into 2: an “index patient” and a “first-degree relative patient” and the presence of BD manifestations were compared between these 2 groups. Results: We identified 864 BD patients (mean age (SD): 47.9 (12) years, disease duration (SD): 83.7 (65.3) months) with 251 (29.1%) having a BD family history. Genital ulcers (P =.002) and papulopustular lesions (P < .001) were detected more frequently in the familial group. Also in the familial group, statistically significant correlations were detected between the index patient and the first-degree relativepatient in terms of erythema nodosum-like lesions (r: 0.398, P: .016), pathergy test positivity (r: 0.561, P: .002), peripheral joint involvement (r: 0.563, P < .001) and vascular involvement (r: 0.408, P: .014). Conclusion: Familial BD may differ from sporadic BD. Additionally, erythema nodosum-like lesions, pathergy test positivity, and vascular and joint involvement may tend to show familial aggregation. Cite this article as: Abacar K, Elif Boncukcuoğlu A, Deniz R, et al. Clinical features and phenotypic similarities of patients with familial Behçet’s disease. Eur J Rheumatol. 2025, 12(2), 0116, doi: 10.5152/eurjrheum.2025.24116.


  • Screening for familial disease presence in first-degree relatives of Behçet’s disease patients: Is measurement of common femoral vein wall thickness valuable for the diagnosis?

    by Ayşe Elif Boncukcuoğlu, Erhan Topal, Rabia Ergelen, Dilara Kaş, Elifnur Alkan, Gamzenur Kaya, Şevket Girgin, Tülin Ergun, Haner Direskeneli, Fatma Alibaz-Oner

    Objectives: We aimed to assess first-degree relatives (FDRs) of Behçet’s disease (BD) patients for the presence of clinical symptoms and signs of BD and evaluate common femoral vein (CFV) wall thickness measurement for the diagnosis. Methods: Patients with BD (n = 129) and FDRs (n = 230) of these patients were included. FDRs were questioned in terms of BD symptoms by phone. Pathergy test and CFV wall thickness measurement were performed among 111 FDRs who accepted the clinical assessment. Clinical assessment groups were classified according to the criteria sets for BD. FDRs who did not meet the criteria sets and had at least one clinical finding in addition to oral aphthae (OA) were categorized as the ‘suspected BD’. Results: : We observed increased frequency of isolated BD manifestations in FDRs. Ten FDRs were diagnosed with BD during clinical evaluation. A significantly increased CFV wall thickness was observed in FDRs of BD patients fulfilling diagnostic BD criteria (P < .001 for both sides) and also in those with suspected BD group (P < .05 for both sides). The presence of OA, genital ulcer, folliculitis, or erythema nodosum was associated with increased CFV wall thickness (P < .05). Conclusion: Our results suggest that the CFV wall thickness measurement can be used in the diagnosis of familial BD.